Inflammation and pancreatic ductal adenocarcinoma: A potential scenario for novel drug targets

Journal of the Pancreas

Volumn 11, Issue 3, 2010, Pages 199-202

  Uomo, Ilaria ^a   Miraglia, Simona ^a   Pastorello, Maurizio ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Chronic; Cyclooxygenase 2; Cytokines; NF kappa B; Pancreatic neoplasms; Pancreatitis; PPAR gamma; Reactive oxygen species

Indexed keywords

CYCLOOXYGENASE 2; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 1BETA; INTERLEUKIN 8; K RAS PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SMAD PROTEIN; SMAD4 PROTEIN; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA;

CANCER GROWTH; CANCER RISK; CELL DAMAGE; CELL DIFFERENTIATION; CELL PROLIFERATION; CIGARETTE SMOKING; DISEASE COURSE; DISEASE MARKER; DNA DAMAGE; EDITORIAL; GENE MUTATION; HIGH RISK PATIENT; HUMAN; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREATITIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; RISK FACTOR; TARGET CELL; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANTIOXIDANTS; CARCINOMA, PANCREATIC DUCTAL; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; NF-KAPPA B; PANCREATIC NEOPLASMS; PANCREATITIS; PPAR GAMMA;

EID: 77953675688     PISSN: None     EISSN: 15908577     Source Type: Journal    
DOI: None     Document Type: Editorial

References (35)

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420:860-7. [PMID 12490959]
2. Farrow B, Evers BM. Inflammation and the development of pancreatic cancer. Surg Oncol 2002; 10:153-69. [PMID 12020670]
3. Algül H, Treiber M, Lesina M, Schmid RM. Mechanisms of disease: chronic inflammation and cancer in the pancreas--a potential role for pancreatic stellate cells? Nat Clin Pract Gastroenterol Hepatol 2007; 4:454-62. [PMID 17667994]
4. Whitcomb DC, Gorry MC, Preston RA, Furey W, Sossenheimer MJ, Ulrich CD, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996; 14:141-5. [PMID 8841182]
5. Whitcomb DC, Applebaum S, Martin SP. Hereditary pancreatitis and pancreatic carcinoma. Ann N Y Acad Sci 1999; 880:201-9. [PMID 10415865]
6. Howes N, Lerch MM, Greenhalf W, Stocken D, Ellis I, Simon P, et al. Clinical and genetic characteristics of hereditary pancreatitis in Europe. Clin Gastroenterol Hepatol 2004; 2:252-61. [PMID 15017610]
7. Lowenfels AB, Maissoneuve P, Cavallini G, Amman RW, Lankisch PG, Andersen JR, et al. Pancreatitis and the risk of pancreatic cancer. International Pancreatitis Study Group. N Engl J Med 1993; 328:1433-7. [PMID 8479461]
8. Rozenblum E, Schutte M, Goggins M, Hahn SA, Panzer S, Zahurak M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997; 57:1731-4. [PMID 9135016]
9. Hruban RH, Wilentz RE, Kern SE. Genetic progression in the pancreatic ducts. Am J Pathol 2000; 156:1821-5. [PMID 10854204]
10. Greer JB, Whitcomb DC. Inflammation and pancreatic cancer: an evidence-based review. Curr Opin Pharmacol 2009; 9:411-8. [PMID 19589727]
11. Baldwin AS Jr. Series introduction: the transcription factor NFkappaB and human disease. j Clin Invest 2001; 107:3-6. [PMID 11134170]
12. Wiseman H, Haliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem J 1996; 313:17-29. [PMID 8546679]
13. Woutersen RA, Appel MJ, Van Garderen-Hoetmer A. Modulation of pancreatic carcinogenesis by antioxidants. Food Chem Toxicol 1999; 37:981-4. [PMID 10541454]
14. Kliewer SA, Wilson TM. The nuclear receptor PPARγ-bigger than fat. Curr Opin Genet Dev 1998; 8:576-81. [PMID 9794815]
15. Cho N, Momose Y. Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers: from the discovery to recent progress. Curr Top Med Chem 2008; 8:1483-507. [PMID 19075761]
16. Krentz AJ, Patel MB, Bailey CJ. New drugs for type 2 diabetes mellitus: what is their place in therapy? Drugs 2008; 68:2131-62. [PMID 18840004]
17. Nakajima A, Tomimoto A, Fujita K, Sugiyama M, Takahashi H, Ikeda I, et al. Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci 2008; 99:1892-900. [PMID 19016747]
18. Dong YW, Wang XP, Wu K. Suppression of pancreatic carcinoma growth by activating peroxisome proliferator-activated receptor gamma involves angiogenesis inhibition. World J Gastroenterol 2009; 15:441-8. [PMID 19152448]
19. Eibl G. The role of PPAR-gamma and its interaction with COX-2 in pancreatic cancer. PPAR Res 2008; 2008:326915. [PMID 18615182]
20. Fesinmeyer MD, Stanford JL, Brentnall TA, Mandelson MT, Farin FM, Srinouanprachanh S, et al. Association between the peroxisome proliferator-activated receptor gamma Pro12Ala variant and haplotype and pancreatic cancer in a high-risk cohort of smokers: a pilot study. Pancreas 2009; 38:631-7. [PMID 19436234]
21. Giaginis C, Katsamangou E, Tsourouflis G, Zizi-Serbetzoglou D, Kouraklis G, Theocharis S. Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit 2009; 15:148-56. [PMID 19396032]
22. Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 2005; 13:559-83. [PMID 15756426]
23. Chen YF, Jobanputra P, Barton P, Bryan S, Fry-Smith A, Harris G, Taylor RS. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Health Technol Assess 2008; 12:1-278. [PMID 18405470]
24. Seo SW, Jung WS, Piao TG, Hong SH, Yun KJ, Park RK, et al. Selective cyclooxygenase-2 inhibitor ameliorates cholecystokininoctapeptide-induced acute pancreatitis in rats. World J Gastroenterol 2007; 13:2298-304. [PMID 17511027]
25. Talukdar R, Saikia N, Singal DK, Tandon R. Chronic pancreatitis: evolving paradigms. Pancreatology 2006; 6:440-9. [PMID 16847381]
26. Hermanova M, Trna J, Nenutil R, Dite P, Kala Z. Expression of COX-2 is associated with accumulation of p53 in pancreatic cancer: analysis of COX-2 and p53 expression in premalignant and malignant ductal pancreatic lesions. Eur J Gastroenterol Hepatol 2008; 20:732-9. [PMID 18617777]
27. Albazaz R, Verbeke CS, Rahman SH, McMahon MJ. Cyclooxygenase-2 expression associated with severity of PanIN lesions: a possible link between chronic pancreatitis and pancreatic cancer. Pancreatology 2005; 5:361-9. [PMID 15980665]
28. Whitcomb DC. Clinical practice. Acute pancreatitis. N Engl J Med 2006; 354:2142-5. [PMID 16707751]
29. Aoki H, Ohnishi H, Hama K, Shinozaki S, Kita H, Osawa H, et al. Cyclooxygenase-2 is required for activated pancreatic stellate cells to respond to proinflammatory cytokines. Am J Physiol Cell Physiol 2007; 292:259-68. [PMID 16837651]
30. Moses AG, Maingay J, Sangster K, Fearon CH, Ross JA. Proinflammatory cytokine release by peripheral blood mononuclear cells from patients with advanced pancreatic cancer: relationship to acute phase response and survival. Oncol Rep 2009; 21:1091-5. [PMID 19288013]
31. Falconer JS, Fearon KC, Plester CE, Ross JA, Carter DC. Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer. Ann Surg 1994; 219:325-31. [PMID 7512810]
32. Uomo G, Gallucci F, Rabitti PG. Anorexia-cachexia syndrome in pancreatic cancer: recent development in research and management. JOP. J Pancreas (Online) 2006; 6:157-62. [PMID 16525199]
33. Istituto Nazionale di Statistica (National Institute of Statistics). Cause di morte 2001 (Causes of deaths, 2001). Annuario ISTAT 2007.
34. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 2009; 6:699-708. [PMID 19806144]
35. Whitcomb D, Greer J. Germ-line mutations, pancreatic inflammation, and pancreatic cancer. Clin Gastroenterol Hepatol 2009; 7(11 Suppl):S29-34. [PMID 19896094]